Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 10th Preview)
-
FDA gene therapy approval
Regeneron’s Otarmeni (lunsotogene parvec-cwha) won FDA accelerated approval as the first in vivo gene therapy for OTOF-related severe-to-profound sensorineural hearing loss. The FDA based its decision on hearing sensitivity improvements at week 24 in the Phase I/II CHORD trial (NCT05788536), with 80% of participants (16 of 20) improving to ≤70 dB HL on pure-tone audiometry. In the study, patients received a single dose via intracochlear infusion, and responses were maintained through follow-up to week 48. Regeneron said 42% of participants achieved normal hearing that included whispers (≤25 dB HL). The FDA noted that the accelerated approval is contingent on confirmatory benefit in the CHORD trial. Regeneron also said it will make Otarmeni available for free in the U.S., and the approval used the agency’s Commissioner’s National Priority Voucher (CNPV) pilot program. For the biotech sector, the decision underscores the growing use of priority and accelerated pathways for first-of-kind neurosensory gene therapies.
-
Infectious disease vaccine R&D signals
Moderna’s reported early-stage hantavirus vaccine work triggered investor attention after reports surfaced that the company has started research on a potential jab. The project is described as in its earliest phases, with clinical development typically taking years before a product is widely available. The reporting cites collaborators including the US Army Medical Research Institute of Infectious Diseases and Korea University’s Vaccine Innovation Center. The move comes amid renewed public focus following a World Health Organization-described cluster tied to cruise travel, which has included confirmed infections and deaths. For biotech watchers, the key issue is the timing and readiness of pipeline targets with no approved hantavirus vaccine to date. If Moderna advances, it may offer a familiar mRNA platform pathway into a therapeutically underserved zoonotic threat.
-
Cell therapy company funding
Odyssey Therapeutics priced an upsized IPO and concurrent private placement to raise $304 million as it advances its lead Phase II program for ulcerative colitis and plans further development across autoimmune disease. The company’s offering totals 15.5 million shares at $18 per share, with an affiliate of TPG Life Sciences Innovations buying 1.39 million shares at the same price. Odyssey’s lead asset, OD-001, is an oral small-molecule inhibitor targeting RIPK2, and the company plans mid-stage trials for the small molecule in combination with Takeda’s Entyvio and as monotherapy. The financing also supports bringing its SLC15A4 program into the clinic for lupus. The IPO move—Odyssey’s second attempt after earlier withdrawing its IPO filing—signals ongoing investor appetite for autoimmune programs with clear clinical catalysts and near-term trial plans.
-
FDA/biopharma regulatory and access decisions
Regulatory timelines shifted for Alzheimer’s therapy lecanemab (Leqembi) as the FDA delayed a decision on the company’s proposed subcutaneous route. Biogen and Eisai said the decision date was moved to August 24 after the agency requested additional information. The update comes as Biogen and Eisai pursue next-generation formulations intended to improve administration convenience and access. In parallel with this regulatory item, the same reporting segment noted other market events including a capital raise by Artiva and pricing activity by Pharvaris. For biotech industry teams, the practical takeaway is near-term uncertainty on formulation milestones and the knock-on effect on partnering, reimbursement planning, and launch sequencing—especially as subcutaneous convenience becomes a central lever for specialty neurodegenerative franchises.
-
Oncology molecule diagnostics and reimbursement momentum
Guardant Health beat expectations with a Q1 2026 revenue surge, raised full-year guidance, and pointed to continued momentum in oncology and screening. The company reported Q1 revenue of $301.7 million, up 48% year over year, and increased its 2026 revenue outlook to $1.30 billion–$1.32 billion. Guardant said growth was driven by minimal residual disease testing volume and reimbursement, including Reveal volumes more than doubling year over year. The firm also highlighted an upgrade to Guardant360 Tissue to include whole-transcriptome RNA testing, describing the change as a potential volume catalyst. Beyond financials, the company said it has submitted data packages to CMS’s MolDx program across breast cancer surveillance, immunotherapy monitoring, and chemotherapy monitoring. For the biotech industry, these CMS-linked steps can materially affect adoption and reimbursement pathways for liquid biopsy platforms.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.